Hospital Mortality in Patients Submitted to Pharmacoinvasive Strategy With Tenecteplase (TNK)
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
This study has the following objective:
To identify related factors to hospital mortality in patients with ST-segment elevation acute myocardial infarction submitted to pharmacoinvasive strategy within a structured healthcare network.
| Condition |
|---|
|
Acute Coronary Syndrome |
| Study Type: | Observational [Patient Registry] |
| Study Design: | Observational Model: Cohort Time Perspective: Prospective |
| Target Follow-Up Duration: | 15 Days |
| Official Title: | Hospital Mortality After ST Segment Elevation Acute Myocardial Infarction Submitted to Pharmacoinvasive Strategy With Tenecteplase (TNK): Analysis of 398 Patients. |
- Hospital Mortality [ Time Frame: During hospital stay,an expected average of 15 days ] [ Designated as safety issue: No ]
| Enrollment: | 368 |
| Study Start Date: | November 2010 |
| Study Completion Date: | October 2012 |
| Primary Completion Date: | October 2012 (Final data collection date for primary outcome measure) |
Primary percutaneous coronary intervention is the main therapy for patients with ST-segment elevation acute myocardial infarction. However, a significant portion of these patients won't receive optimal treatment due to the small number of tertiary centers with interventional laboratories available for 24 hours a day, 7 days a week.
Specially in large urban centers and rural areas, where tertiary care hospitals are restricted to a specific region, alternative approaches must be developed. The pharmacoinvasive strategy has emerged as an alternative for patients admitted to primary care centers. It is based in up-front intravenous thrombolytic therapy and transfer to a tertiary center where early, systematic, coronary intervention will be performed between 3 to 24 hours after the administration of thrombolytic drugs, even in cases in which successful reperfusion was obtained.
Eligibility| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
| Sampling Method: | Non-Probability Sample |
The patients will be selected from primary care clinic.
Inclusion Criteria:
- Clinical diagnosis of ST-segment elevation acute myocardial infarction submitted to pharmacoinvasive strategy with tenecteplase.
Exclusion Criteria:
- Absence of obstructive coronary disease
- Surgical reference
- Did not undergo catheterization
Contacts and Locations| Brazil | |
| Federal University of Sao Paulo | |
| Sao Paulo, SP, Brazil | |
| Principal Investigator: | Felipe JA Falcao | Federal University of Sao Paulo |
| Principal Investigator: | Claudia MR Alves, Doctor | Federal University of Sao Paulo |
| Study Director: | Antonio CC Carvalho | Federal University of Sao Paulo |
| Study Director: | Adriano HP Barbosa | Federal University of Sao Paulo |
More Information
No publications provided
| Responsible Party: | Felipe José de Andrade Falcão, Master, Federal University of São Paulo |
| ClinicalTrials.gov Identifier: | NCT01791764 History of Changes |
| Other Study ID Numbers: | SAMU-01 |
| Study First Received: | February 8, 2013 |
| Last Updated: | February 12, 2013 |
| Health Authority: | Brazil: Ministry of Health |
Additional relevant MeSH terms:
|
Myocardial Infarction Acute Coronary Syndrome Myocardial Ischemia Heart Diseases Cardiovascular Diseases Vascular Diseases Angina Pectoris Chest Pain Pain |
Signs and Symptoms Tenecteplase Fibrinolytic Agents Fibrin Modulating Agents Molecular Mechanisms of Pharmacological Action Pharmacologic Actions Cardiovascular Agents Therapeutic Uses Hematologic Agents |
ClinicalTrials.gov processed this record on June 17, 2013